{
   "press": [
       {
           "date": "Febuary 14, 2017",
           "title": "Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV"
       },
       {
          "date": "Febuary 08, 2017",
           "title": "Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22"
       },
       {
           "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend"
           
       },
       {
          "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results"
       },
       {
           "date": "Febuary 14, 2017",
           "title": "Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV"
       },
       {
          "date": "Febuary 08, 2017",
           "title": "Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22"
       },
       {
           "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend"
           
       },
       {
          "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results"
       },
       {
           "date": "Febuary 14, 2017",
           "title": "Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors"
       },
       {
          "date": "Febuary 13, 2017",
           "title": "Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV"
       },
       {
          "date": "Febuary 08, 2017",
           "title": "Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22"
       },
       {
           "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend"
           
       },
       {
          "date": "Febuary 07, 2017",
           "title": "Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results"
       }
   ]
}